BioNTech to Buy CureVac in $1.25B Stock Deal That Would Also End mRNA Patent Dispute

BioNTech, a biotech company best known for its successful development of a messenger RNA Covid-19 vaccine, is acquiring fellow mRNA company CureVac in a $1.25 billion stock deal that ...